Galapagos has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director, effective February 9, 2026, succeeding Dr. Susanne Schaffert. Dr. Fontoura brings extensive pharmaceutical leadership experience from Roche, and his appointment is expected to bolster Galapagos’ strategic oversight as it advances innovative medicines and business development. Analysts currently rate GLPG stock as a Sell with a $22.00 price target, while TipRanks’ AI Analyst, Spark, assigns a Neutral rating due to challenging financial and operational landscapes despite a strong cash position.
Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.
Galapagos Adds Industry Veteran Paulo Fontoura to Board as Independent Director
Galapagos has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director, effective February 9, 2026, succeeding Dr. Susanne Schaffert. Dr. Fontoura brings extensive pharmaceutical leadership experience from Roche, and his appointment is expected to bolster Galapagos’ strategic oversight as it advances innovative medicines and business development. Analysts currently rate GLPG stock as a Sell with a $22.00 price target, while TipRanks’ AI Analyst, Spark, assigns a Neutral rating due to challenging financial and operational landscapes despite a strong cash position.